DK1044015T3 - Formuleringer med amylinagonistpeptider og insulin - Google Patents

Formuleringer med amylinagonistpeptider og insulin

Info

Publication number: DK1044015T3
Authority: DK; Denmark
Prior art keywords: approximately; formulations; insulin; amylin agonist; agonist peptides
Prior art date: 1998-01-09

Application number

DK98902423T

Other languages

English (en)

Inventor

Italian James L

Shankar Musunuri

Cale Ruby

Original Assignee

Amylin Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-01-09

Filing date

1998-01-09

Publication date

2008-12-08

1998-01-09 Application filed by Amylin Pharmaceuticals Inc filed Critical Amylin Pharmaceuticals Inc

2008-12-08 Application granted granted Critical

2008-12-08 Publication of DK1044015T3 publication Critical patent/DK1044015T3/da

Links

NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title abstract 4
239000000203 mixture Substances 0.000 title abstract 4
238000009472 formulation Methods 0.000 title abstract 3
102000004877 Insulin Human genes 0.000 title abstract 2
108090001061 Insulin Proteins 0.000 title abstract 2
108010041872 Islet Amyloid Polypeptide Proteins 0.000 title abstract 2
102000036770 Islet Amyloid Polypeptide Human genes 0.000 title abstract 2
239000000556 agonist Substances 0.000 title abstract 2
229940125396 insulin Drugs 0.000 title abstract 2
102000004196 processed proteins & peptides Human genes 0.000 title 1
108090000765 processed proteins & peptides Proteins 0.000 title 1
RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 abstract 2
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 abstract 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 abstract 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 abstract 1
229910019142 PO4 Inorganic materials 0.000 abstract 1
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 abstract 1
150000001720 carbohydrates Chemical class 0.000 abstract 1
229930195712 glutamate Natural products 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 abstract 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract 1
239000010452 phosphate Substances 0.000 abstract 1
108010029667 pramlintide Proteins 0.000 abstract 1
229960003611 pramlintide Drugs 0.000 abstract 1
NRKVKVQDUCJPIZ-MKAGXXMWSA-N pramlintide acetate Chemical compound C([C@@H](C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCCCN)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 NRKVKVQDUCJPIZ-MKAGXXMWSA-N 0.000 abstract 1
229940071643 prefilled syringe Drugs 0.000 abstract 1
239000003755 preservative agent Substances 0.000 abstract 1
230000002335 preservative effect Effects 0.000 abstract 1
150000005846 sugar alcohols Polymers 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Organic Chemistry (AREA)
Endocrinology (AREA)
Bioinformatics & Cheminformatics (AREA)
Oil, Petroleum & Natural Gas (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Obesity (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Immunology (AREA)
Dermatology (AREA)
Toxicology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)

DK98902423T 1998-01-09 1998-01-09 Formuleringer med amylinagonistpeptider og insulin DK1044015T3 (da)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
PCT/US1998/000288 WO1999034822A1 (en)	1998-01-09	1998-01-09	Formulations for amylin agonist peptides

Publications (1)

Publication Number	Publication Date
DK1044015T3 true DK1044015T3 (da)	2008-12-08

Family

ID=22266167

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK98902423T DK1044015T3 (da)	1998-01-09	1998-01-09	Formuleringer med amylinagonistpeptider og insulin

Country Status (9)

Country	Link
EP (1)	EP1044015B1 (da)
JP (1)	JP4353544B2 (da)
AT (1)	ATE410182T1 (da)
AU (1)	AU760609B2 (da)
CA (1)	CA2365742C (da)
DE (1)	DE69840106D1 (da)
DK (1)	DK1044015T3 (da)
ES (1)	ES2316161T3 (da)
WO (1)	WO1999034822A1 (da)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1998005351A1 (en)	1996-08-08	1998-02-12	Amylin Pharmaceuticals, Inc.	Methods for regulating gastrointestinal motility
US5783556A (en) *	1996-08-13	1998-07-21	Genentech, Inc.	Formulated insulin-containing composition
US7312196B2 (en) *	1997-01-08	2007-12-25	Amylin Pharmaceuticals, Inc.	Formulations for amylin agonist peptides
JP4647736B2 (ja) *	1999-09-30	2011-03-09	小林製薬株式会社	薬剤発散具
EP2036539A1 (en)	2007-09-11	2009-03-18	Novo Nordisk A/S	Stable formulations of amylin and its analogues
CN101822822A (zh) *	2009-03-04	2010-09-08	北京德众万全药物技术开发有限公司	一种普兰林肽的药物组合物及其制备方法
JP2009149684A (ja) *	2009-03-11	2009-07-09	Amylin Pharmaceut Inc	アミリン作動薬ペプチド用製剤
CN102145164B (zh) *	2010-12-16	2013-02-27	深圳市健元医药科技有限公司	一种更加稳定的iapp类似物注射剂
US9399065B2 (en)	2012-04-16	2016-07-26	Biodel Inc.	Magnesium compositions for modulating the pharmacokinetics and injection site pain of insulin
UA116217C2 (uk)	2012-10-09	2018-02-26	Санофі	Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
SG10201705097PA (en)	2012-12-21	2017-07-28	Sanofi Sa	Functionalized exendin-4 derivatives
EP3080154B1 (en)	2013-12-13	2018-02-07	Sanofi	Dual glp-1/gip receptor agonists
WO2015086728A1 (en)	2013-12-13	2015-06-18	Sanofi	Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
TW201609797A (zh)	2013-12-13	2016-03-16	賽諾菲公司	雙重ｇｌｐ－１／升糖素受體促效劑
TW201609796A (zh)	2013-12-13	2016-03-16	賽諾菲公司	非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
TW201625669A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625670A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh)	2014-04-07	2016-07-16	賽諾菲公司	作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
US10072060B2 (en)	2014-05-02	2018-09-11	The Research Foundation For The State University Of New York	Islet amyloid polypeptides with improved solubility
US9932381B2 (en)	2014-06-18	2018-04-03	Sanofi	Exendin-4 derivatives as selective glucagon receptor agonists
AR105319A1 (es)	2015-06-05	2017-09-27	Sanofi Sa	Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
AR105284A1 (es)	2015-07-10	2017-09-20	Sanofi Sa	Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
CN107952064B (zh) *	2016-10-14	2023-10-20	江苏豪森药业集团有限公司	含有聚乙二醇洛塞那肽的药物制剂及其制备方法
WO2018122278A1 (fr) *	2016-12-27	2018-07-05	Adocia	Compositions sous forme de solution aqueuse injectable comprenant de l'amyline, un agoniste au récepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
US11028137B2 (en)	2017-02-01	2021-06-08	The Research Foundation For The State University Of New York	Mutant islet amyloid polypeptides with improved solubility and methods for using the same
HRP20240485T1 (hr)	2017-08-24	2024-07-05	Novo Nordisk A/S	Pripravci glp-1 i njihova upotreba
US11110063B2 (en)	2017-08-25	2021-09-07	MAIA Pharmaceuticals, Inc.	Storage stable sincalide formulations
MX2022009844A (es) *	2020-02-18	2022-09-05	Novo Nordisk As	Composiciones y usos del peptido similar al glucagon-1 (glp-1).
KR20230121822A (ko) *	2020-12-16	2023-08-21	질랜드 파마 에이/에스	Glp-1/glp-2 이중 효능제의 약학적 조성물
US20240335513A1 (en) *	2022-05-30	2024-10-10	Zealand Pharma A/S	Liquid formulations of amylin analogues

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4654324A (en) *	1981-08-27	1987-03-31	Eli Lilly And Company	Human proinsulin pharmaceutical formulations
US5321008A (en) *	1991-01-10	1994-06-14	Amylin Pharmaceuticals, Inc.	Methods and compositions for treatment of diabetes mellitus, hypoglycemia, and other conditions
ES2161697T3 (es) *	1991-11-19	2001-12-16	Amylin Pharmaceuticals Inc	Peptidos agonistas de amilina y usos de los mismos.
US6143718A (en) *	1995-06-07	2000-11-07	Amylin Pharmaceuticals, Inc.	Treatment of Type II diabetes mellutis with amylin agonists
US7910548B2 (en) *	1997-06-06	2011-03-22	Amylin Pharmaceuticals, Inc.	Methods for treating obesity

1998
- 1998-01-09 DK DK98902423T patent/DK1044015T3/da active
- 1998-01-09 DE DE69840106T patent/DE69840106D1/de not_active Expired - Lifetime
- 1998-01-09 ES ES98902423T patent/ES2316161T3/es not_active Expired - Lifetime
- 1998-01-09 CA CA2365742A patent/CA2365742C/en not_active Expired - Fee Related
- 1998-01-09 EP EP98902423A patent/EP1044015B1/en not_active Expired - Lifetime
- 1998-01-09 WO PCT/US1998/000288 patent/WO1999034822A1/en not_active Ceased
- 1998-01-09 JP JP53493999A patent/JP4353544B2/ja not_active Expired - Fee Related
- 1998-01-09 AU AU59094/98A patent/AU760609B2/en not_active Ceased
- 1998-01-09 AT AT98902423T patent/ATE410182T1/de not_active IP Right Cessation

Also Published As

Publication number	Publication date
ES2316161T3 (es)	2009-04-01
WO1999034822A1 (en)	1999-07-15
ATE410182T1 (de)	2008-10-15
EP1044015A1 (en)	2000-10-18
CA2365742C (en)	2013-04-30
CA2365742A1 (en)	1999-07-15
JP2002511103A (ja)	2002-04-09
EP1044015B1 (en)	2008-10-08
AU760609B2 (en)	2003-05-15
JP4353544B2 (ja)	2009-10-28
AU5909498A (en)	1999-07-26
DE69840106D1 (de)	2008-11-20
EP1044015A4 (en)	2001-05-23

Publication	Publication Date	Title
DK1044015T3 (da)	2008-12-08	Formuleringer med amylinagonistpeptider og insulin
ES2569949T3 (es)	2016-05-13	Formulaciones farmacéuticas que comprenden un péptido complejado con una dicetopiperazina
US5766582A (en)	1998-06-16	Stable, aqueous alfa interferon solution formulations
CA2295140A1 (en)	1998-12-17	Stable insulin formulations
HU202761B (en)	1991-04-29	Process for producing stabilized erythropoietin compositions
EP2586459B1 (en)	2017-05-24	Vegf antagonist formulations
JPH0430926B2 (da)	1992-05-25
WO2003101395A3 (en)	2004-10-14	Formulations for amylin agonist peptides
EA004761B1 (ru)	2004-08-26	Стабилизированная жидкая композиция паратиреоидного гормона, флакон с композицией и способы их получения
DE59908745D1 (de)	2004-04-08	Pharmazeutische ciclosporin-formulierung mit verbesserten biopharmazeutischen eigenschaften, erhöhter physikalischer qualität & stabilität sowie verfahren zur herstellung
ES2089011T3 (es)	1996-10-01	Excipiente lipidico de administracion nasal y aplicacion topica.
JP2009091363A (ja)	2009-04-30	Ｐｔｈの安定化水溶液注射剤
AR040529A1 (es)	2005-04-13	Formulaciones de hgh en alta concentracion que contienen 1,2-propilenglicol
ATE228005T1 (de)	2002-12-15	Pharmazeutische formulierungen aus corticotropin freisetzenden faktor mit verbesserter stabilitaet in fluessiger form
KR19980031737A (ko)	1998-07-25	안정한 프로스타글란딘 e1-함유 주사제 조성물
JPH06247872A (ja)	1994-09-06	高濃度ｔｃｆ製剤
US4963529A (en)	1990-10-16	Stable growth hormone releasing factor preparation
JP4252260B2 (ja)	2009-04-08	Ｐｔｈの安定化水溶液注射剤
JPH1149698A (ja)	1999-02-23	安定性を向上させたラクトフェリンの水性製剤
Uebel et al.	2001	Stability evaluation of a prostaglandin E1 saline solution packed in insulin syringes
WO2004108061A2 (en)	2004-12-16	Stable injectable pharmaceutical composition of thiopental; method for stabilizing aqueous solutions of thiopental and, use of thiopental for producing a medicament
AHMAD et al.	1999	Stability of chlorpheniramine maleate in cough syrups
JPH10298102A (ja)	1998-11-10	カルシトニン注射液
JPH10287569A (ja)	1998-10-27	アシクロビル又はその塩の輸液型キット注射剤
JPH07138184A (ja)	1995-05-30	エルカトニン水性注射用製剤